Therapeutic Hypothermia for HIE: Indian NICU Protocol & Drug Interactions Guide

Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: Saving Brains in Indian NICUs

Hypoxic-ischemic encephalopathy (HIE) is the most common cause of neonatal brain injury, affecting 1-6 per 1000 live births globally and an estimated 3-5 per 1000 live births in India. Birth asphyxia contributes to approximately 23% of the estimated 2.5 million global neonatal deaths annually, with India bearing a disproportionate burden. Therapeutic hypothermia (TH) is the only proven neuroprotective intervention for moderate-to-severe HIE, reducing the combined outcome of death or major neurodisability by approximately 25%. Every Indian Level III NICU should be equipped to offer this therapy, and Level II units must be capable of initiating passive cooling during transport.

The Science Behind Cooling

HIE brain injury occurs in two phases: the primary injury during the hypoxic-ischemic event, and a secondary injury phase beginning 6-24 hours later driven by excitotoxicity, oxidative stress, inflammation, and apoptosis. Therapeutic hypothermia works by:

• Reducing cerebral metabolic rate by 5-8% per degree Celsius reduction
• Decreasing excitatory neurotransmitter release (glutamate)
• Attenuating free radical production and oxidative stress
• Reducing inflammatory cytokine production
• Inhibiting apoptotic pathways (caspase activation)
• Preserving the blood-brain barrier integrity

Eligibility Criteria (NNF India Adapted)

Criterion A: Evidence of Perinatal Asphyxia (Any ONE of the Following)

• Apgar score 5 or below at 10 minutes of age
• Need for positive pressure ventilation or CPR at 10 minutes
• Cord blood or arterial pH below 7.0 within 60 minutes of birth
• Base deficit above 16 mEq/L in cord or arterial blood within 60 minutes

Criterion B: Evidence of Moderate-to-Severe Encephalopathy

Feature	Moderate (Sarnat Stage 2)	Severe (Sarnat Stage 3)
Level of consciousness	Lethargic	Comatose
Spontaneous activity	Decreased	Absent
Posture	Distal flexion	Decerebrate
Tone	Hypotonia (focal or general)	Flaccid
Primitive reflexes (suck)	Weak	Absent
Autonomic (pupils)	Constricted	Dilated or fixed
Seizures	Common	Uncommon (too suppressed)

Both Criterion A AND Criterion B must be met for therapeutic hypothermia eligibility.

Cooling Protocol

Whole-Body Cooling (Standard Method)

Phase	Target Temperature	Duration	Method
Induction	Achieve 33.5 degrees C	Within 60-90 minutes	Servo-controlled cooling device; or passive cooling with gel packs and continuous monitoring
Maintenance	33.5 degrees C (33.0-34.0 range)	72 hours	Servo-controlled preferred; manual adjustment if using low-cost methods
Rewarming	Rising 0.5 degrees C per hour	6-12 hours	Gradual; servo-controlled or incremental radiant warmer adjustment

Temperature Monitoring: Continuous core temperature monitoring (rectal probe preferred, esophageal acceptable) is MANDATORY throughout cooling. Skin temperature monitoring alone is insufficient. Temperature below 32 degrees C increases risk of cardiac arrhythmia, coagulopathy, and PPHN and must be avoided.

Drug Dose Adjustments During Hypothermia

Hypothermia significantly alters drug pharmacokinetics by reducing hepatic enzyme activity, renal blood flow, and protein binding. The following adjustments are critical:

Drug	Standard Dose	Adjustment During Cooling	Rationale
Phenobarbital	Maintenance 3-5 mg/kg/day	Extend interval to q24h; monitor levels	Reduced hepatic clearance; half-life prolonged by 30-40%
Gentamicin	4-5 mg/kg q24h	Extend to q36-48h; check trough levels	Reduced renal clearance
Morphine	0.05-0.1 mg/kg q4-6h	Reduce dose by 30%; extend to q6-8h	Reduced hepatic glucuronidation
Fentanyl	1-2 mcg/kg/hr infusion	Reduce by 25-30%	Reduced hepatic clearance via CYP3A4
Ampicillin	50 mg/kg q12h	No major adjustment needed	Minimal change in clearance
Dopamine/Dobutamine	Standard doses	May need lower doses; titrate to effect	Altered receptor sensitivity; reduced metabolism
Midazolam	0.05-0.1 mg/kg	Reduce dose; extend interval	Reduced hepatic CYP3A4 metabolism

Rewarming Drug Adjustments

During rewarming, drug metabolism accelerates back to normal as body temperature rises. This can lead to subtherapeutic drug levels if doses are not readjusted:

• Return to standard dosing intervals as temperature normalizes
• Monitor phenobarbital and aminoglycoside levels during and after rewarming
• Watch for increased analgesic requirements as metabolism normalizes
• Be vigilant for seizure recurrence during rewarming (seizures are common in this phase)

Monitoring During Therapeutic Hypothermia

Parameter	Frequency	Target/Notes
Core temperature	Continuous	33.0-34.0 degrees C; alarm for below 32 or above 34.5
Heart rate	Continuous	Sinus bradycardia (HR 80-100) is expected and NOT an indication to stop cooling
Blood pressure	Continuous (invasive preferred)	MAP above gestational age; inotropes if needed
SpO2	Continuous	Pre-ductal 90-95%
aEEG/EEG	Continuous throughout	Track background activity, seizure burden
Blood gas	Every 4-6 hours	Correct values for temperature (alpha-stat approach)
Blood glucose	Every 4-6 hours	Maintain 45-150 mg/dL
Electrolytes (Na, K, Ca, Mg)	Every 12 hours	Correct disturbances promptly
Coagulation (PT, APTT, platelets)	Every 24 hours	Hypothermia worsens coagulopathy; treat DIC if present
Liver and renal function	Every 24 hours	HIE causes multiorgan injury
Cranial ultrasound	Day 1, 3, 7	Screen for hemorrhage; MRI at day 5-7 for prognostication

Common Complications During Cooling

• Sinus bradycardia: Expected physiological response; HR 80-100 is normal during cooling and NOT an indication to stop
• Coagulopathy: Hypothermia impairs coagulation cascade; monitor and treat with blood products as needed
• Thrombocytopenia: Common during cooling; maintain platelets above 50,000 if not bleeding
• Skin injury: Subcutaneous fat necrosis can occur at contact points with cooling devices; rotate positions
• PPHN: Hypothermia can worsen pulmonary vascular resistance; may need iNO therapy
• Feeding intolerance: Gut motility reduced; feeds are typically withheld during cooling and started during rewarming
• Hypoglycemia: Monitor closely; hypothermia reduces insulin clearance and may cause variable glucose levels

Low-Cost Cooling Methods for Indian NICUs

Recognizing that servo-controlled cooling devices may not be available in all Indian settings, NNF India and the Indian Council of Medical Research (ICMR) support the use of validated low-cost cooling methods:

MiraCradle

An Indian-manufactured phase-changing material (PCM) cooling device validated in clinical trials. It uses PCM gel packs that maintain a temperature of 33-34 degrees C without electricity. Cost-effective and suitable for Level II and III NICUs across India.

Gel Pack Cooling

Frozen gel packs (partially thawed to 10-15 degrees C) applied to the head, trunk, and extremities with continuous rectal temperature monitoring. Requires trained nursing staff and intensive temperature surveillance to avoid overcooling.

Key Principles for Low-Cost Cooling

• Continuous rectal temperature monitoring is absolutely mandatory regardless of the cooling method
• Dedicated nursing ratio (1:1) during cooling for temperature surveillance
• Clear overcooling and undercooling protocols must be in place
• Transport cooling protocols for transfers from Level II to Level III centers

Rewarming Protocol

Rewarming is a critical phase that must be performed slowly and with vigilance:

1. Begin rewarming after 72 hours of maintained cooling
2. Increase temperature by 0.5 degrees C per hour (maximum)
3. Total rewarming period should be 6-12 hours
4. Monitor for seizure recurrence during rewarming (common due to reperfusion injury)
5. Adjust drug doses back toward standard as temperature normalizes
6. Resume enteral feeding during or after rewarming once temperature is stable at 36.5-37.0 degrees C
7. Continue aEEG monitoring for 24 hours post-rewarming

Prognostication and Follow-Up

After completing therapeutic hypothermia, prognostication should utilize multiple modalities:

• MRI brain: Performed at day 5-7 of life; pattern and extent of injury on diffusion-weighted imaging provides the best prognostic information
• aEEG/EEG: Background pattern at 48-72 hours correlates with outcomes; burst-suppression or flat trace predicts poor outcomes
• Clinical examination: Neurological examination at discharge provides baseline for developmental follow-up
• Long-term follow-up: Developmental assessment at 3, 6, 12, 18, and 24 months using standardized tools (DASII in Indian settings)

Indian NICU Implementation

The adoption of therapeutic hypothermia in Indian NICUs has expanded significantly following NNF India endorsement and availability of low-cost cooling devices. HEAMAC neonatal care resources support this expansion by facilitating access to cooling equipment, continuous temperature monitoring devices, and aEEG machines essential for comprehensive HIE management. Key implementation priorities include training in Sarnat staging, establishing 6-hour initiation windows through improved birth attendant awareness, and developing regional transport cooling protocols for timely referral from Level II to Level III centers.

Conclusion

Therapeutic hypothermia is a proven, life-changing intervention for moderate-to-severe HIE that must be available in every Indian Level III NICU. The 6-hour window for initiation, combined with the need for 72 hours of precise temperature control and careful drug dose adjustments, demands a high level of clinical expertise and nursing dedication. With the availability of low-cost cooling devices validated for Indian settings, the expansion of this therapy to more centers is both feasible and imperative to reduce the devastating burden of HIE-related death and disability in India.